(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.03%) $78.13
(0.84%) $2.16
(-0.26%) $2 302.70
(-0.04%) $26.68
(-0.76%) $957.95
(0.07%) $0.929
(0.00%) $10.87
(0.04%) $0.797
(0.00%) $91.45
Quarter results tomorrow
(bmo 2024-05-07)
Expected move: +/- 10.31%
2.35% $ 2.61
@ $2.49
Emitido: 13 feb 2024 @ 15:29
Retorno: 4.82%
Señal anterior: feb 13 - 09:30
Señal anterior:
Retorno: 0.81 %
Live Chart Being Loaded With Signals
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration...
Stats | |
---|---|
Volumen de hoy | 1.34M |
Volumen promedio | 2.25M |
Capitalización de mercado | 393.16M |
EPS | $0 ( 2024-03-12 ) |
Próxima fecha de ganancias | ( $-0.0800 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.26 |
ATR14 | $0.00400 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-19 | Duarte Ira | Buy | 3 874 | Common Stock |
2024-04-19 | Duarte Ira | Sell | 1 122 | Common Stock |
2024-04-19 | Duarte Ira | Sell | 3 874 | Restricted Stock Units |
2024-04-19 | Forbes William P | Buy | 3 874 | Common Stock |
2024-04-19 | Forbes William P | Sell | 3 874 | Restricted Stock Units |
INSIDER POWER |
---|
66.44 |
Last 96 transactions |
Buy: 15 032 989 | Sell: 3 241 807 |
Volumen Correlación
Heron Therapeutics Inc Correlación
10 Correlaciones Más Positivas | |
---|---|
TTGT | 0.894 |
TFFP | 0.891 |
BMAQ | 0.89 |
BRIVU | 0.889 |
RMRM | 0.888 |
MSDA | 0.885 |
TIOA | 0.884 |
VSTA | 0.884 |
CRWD | 0.884 |
KROS | 0.882 |
10 Correlaciones Más Negativas | |
---|---|
TENX | -0.91 |
TVACW | -0.903 |
BOCH | -0.901 |
NETE | -0.9 |
RELL | -0.899 |
VTNR | -0.898 |
FFIE | -0.895 |
AMRB | -0.894 |
AGRI | -0.893 |
CRCT | -0.893 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Heron Therapeutics Inc Correlación - Moneda/Commodity
Heron Therapeutics Inc Finanzas
Annual | 2023 |
Ingresos: | $127.04M |
Beneficio Bruto: | $61.94M (48.75 %) |
EPS: | $-0.800 |
FY | 2023 |
Ingresos: | $127.04M |
Beneficio Bruto: | $61.94M (48.75 %) |
EPS: | $-0.800 |
FY | 2022 |
Ingresos: | $107.67M |
Beneficio Bruto: | $52.80M (49.04 %) |
EPS: | $-1.240 |
FY | 2021 |
Ingresos: | $87.18M |
Beneficio Bruto: | $41.16M (47.21 %) |
EPS: | $-2.24 |
Financial Reports:
No articles found.
Heron Therapeutics Inc
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico